Given the complexities of primary mitochondrial diseases and, by extension, the challenges of designing informative clinical trials in this group of rare diseases, this scientific symposium will bring together academic physicians, FDA regulatory experts, and experts from related disciplines to exchange ideas on ways to address the challenges and to promote drug development in this challenging field. BSF Executive Director, Emily Milligan will be speaking as a member of the second panel discussion.